[
    {
        "document": "Malow et al. 2012",
        "metadata": {
            "originalPdf": "eac9624b-65fe-412f-b7ab-f9ea82581e16.pdf",
            "originalText": ", which, as\nnoted, are common in ASD. It would be interesting to note\nthat the decrease in the short-chain fatty acid, butyrate, in\nASD may be intimately linked to alterations in circadian\ngene, mitochondrial, immune and melatonergic pathway\nfunctions (Jin et al. 2016; Maes et al. 2019). Microbiome\nderived butyrate increases the melatonergic pathway (Jinet al. 2016), as well as optimizes mitochondrial function,\npartly by acting via BMAL1 and PDC disinhibition, thereby\noptimizing mitochondrial oxidative phosphorylation and\nimmune cell function (Maes et al. 2019). Changes in the gut\nmicrobiome are therefore important to the regulation of the\nimmune response as well as wider effects via the regulation\nof metabolism (Anderson and Maes 2020).\nCircadian pathway: a potential\ntarget of therapy\nMany studies both in animals as well as in humans have\nconvincingly demonstrated that the pharmacological\nmodulators of the circadian clock could emerge as potential\ntherapeutic drugs in diseases where circadian disruption\nplays a critical pathogenetic role (Antoch and Kondratov\n2013). Recent reports suggest that circadian genes could\nserve as potential therapeutic targets in various pathol-\nogies, including cancers (Elshazley et al. 2012). Circadian\nelements could also be considered as important targets of\ntherapy in ASD. Primary evidence towards this has beengarnered from studies on melatonin mediated sleep regu-\nlation in children with ASD. Given its roles in neuro-\ndevelopment, circadian entrainment and sleep regulation\nas well as in ASD risk, melatonin supplementation is a\nputative treatment option for sleep disorders in children\nwith ASD (Lalanne et al. 2021). Melatonin supplementation\nhas shown promising results in treating sleep onset\ninsomnia in children with ASD (Malow et al. 2012, 2021).10\nF. Abdul et al.: Circadian abnormalities in ASD",
            "page": 9
        },
        "id": "205"
    },
    {
        "document": "MJH",
        "metadata": {
            "originalPdf": "Molecular jackhammers eradicate cancer cells.pdf",
            "originalText": "EM media was removed and the cells were washed twice with \nPBS buffer. Then, a mixture of fresh DMEM media without phenol red \nand with the MJH was added to the cells. The DMEM without phenol \nred was from Gen Clone (25–501C) and was supplemented with 10% \nFBS (Corning, 35010CV), 1× MEM non-essential amino acid solution \n(Gibco, 11140050) and penicillin–streptomycin. The cells were incu -\nbated in the presence of the MJH at 37 °C and 5% CO2 for 30 min. Then \nthe cells were imaged and photoactivated in the confocal microscope \n(Nikon A1-Rsi, Plan Apo IR ×60/1.27 water immersion objective and \nNIS-Elements AR5.21.03 software for imaging and data analysis, Rice University Shared Equipment Authority).\nTemperature measurements\nThe cell permeabilization and flow cytometry analysis were conducted \nas described above. The temperature of the cell suspension was meas -\nured using a temperature probe (model SC-TT-K-30-36-PP, Omega \nEngineering) immersed in the media. The same process was repeated with the cell suspension on top of an ice bath. The temperature of the \ncell suspension was recorded in the same way during NIR light illu -\nmination. The temperature of the media remained constant at room \ntemperature (~20 °C) upon illumination of the media with 730 nm LED \nlight at 80 mW cm−2 for 10 min; a minor temperature increase of only \n0.4 °C was observed, which was attributed to the absorption of the \nillumination light by the media. Similarly, on ice, the temperature of \nthe media increased only 0.6 °C due to illumination by the 730 nm LED.\nROS scavenger experiments\nThe cell permeabilization and flow cytometry analysis were conducted \nas described above, but in this case, ROS scavengers (N -acetyl cysteine, \nthiourea, sodium azide, vitamin C or methionine) were added to the \ncell suspension and incubated for 1.5–2 h at 37 °C and 5% CO2 before \nany treatment to allow the antioxidants to interact first and protect \nthe cells.\nCrystal violet cell viability assay\nThe crystal violet assay was used to measure cell viability. This assay \nis based on the principle that viable cells adhere to the surface of the \ncell culture dish, keep growing and remain attached during cell culture \nunder standard conditions for a period of 1–2 days as well as during \nstaining under the conditions of the assay. In contrast, dead cells do \nnot adhere to the surface of the cell culture dish, do not grow and \ndetach easily during the manipulation steps of the assay, which include \nremoval of media, exchange with fresh media and washing with PBS \nbuffer. In the cell viability assay, A375 cells were collected, counted, and \nthen 20,000 A375 cells were added to each well of a 24-well culture plate \n(Corning) and cultured for 1 day under the standard incubation condi -\ntions of 37 °C and 5% CO2. The cells were treated in four experimental ",
            "page": 10
        },
        "id": "745"
    },
    {
        "document": "MT1 and MT2",
        "metadata": {
            "originalPdf": "2019Pinato-MS_Proof.pdf",
            "originalText": " with ASD. Under normal neurodevelopmental conditions, TNF plays a physiological role in controlling apoptosis, neurogenesis, and neuronal cell differentiation [167], which is the biological basis for the development of cognition [168]. Increased levels of TNF result in abnormalities in neural connectivity as well as deficits in the processing information and social interaction [168]. In rodent models, activation of TNF receptors in pinealocytes leads to translocation of the NF-κB p50/p50 subunit, which inhibits Aanat c o d i n g  g e n e  e x p r e s s i o n  [ 1 6 9 ] .  O u r  r e c e n t  s t u d y  c o n f i r m e d  that in ASD there is an inverse correlation between melatonin and TNF levels, suggesting the relevance of pineal dysfunction in ASD mediated by inflammation [153]. Several other studies have shown that the pinealocytes express immunological receptors that may recognize pathogens and other cytokines, as well as the cytokine TNF [68, 163, 169, 170]. Thus, it is plausible to hypothesize that neurodevelopment in ASD subjects may be a result of intra-uterine milieu, genetic polymorphisms driven by circadian clock genes, or genes involved in neuroendocrine responses, but also the activation of the immune-pineal axis, which remains off genetic changes and is a consequence of increased inflammation.  One of the premises of the activation of the immune pineal axis relies on its ability to induce the so-called, ‘extra-pineal’ synthesis of melatonin outside the pineal gland. It is a matter of mention that this extra-pineal synthesis of melatonin does not follow the cir-cadian orchestration, and thus, it is not thought to be a response derived from the SCN. On the other hand, melatonin synthesized rhythmically at the retina, but not under control of the SCN, relies as a major source for allowing retinal cell arrangement and prevent-ing light-induced retinal damage [171,172]. On the other hand, extra-pineal synthesis of melatonin, besides a beneficial signal, maybe indicates chronodisruption, but still, prevent tissue damage.   Once synthesized, the pineal-derived melatonin is immediately released into the systemic circulation to reach peripheral and central target tissues. At this level, the melatonin distributes a noctur-nal/circadian message within the entire body to regulate daily and physiological rhythms through different molecular pathways. On the other hand, extra-pineal synthesis of melatonin orchestrates non-rhythmic aspects of cellular defense in the cell of production, which may include an increase in phagocytosis and cell survival [64]. Independently on the local of its synthesis, the most well-characterized pathway for melatonin transduction is the binding and activation of the membrane specific G protein-coupled melatonin receptors MT1 and MT2 [173]. Both receptors were found to pre-sent day/night differences in expression in the SCN of rats and pri-mates, as well in other hypothalamic areas involved in the regula-tion of biological rhythms [174]. The identification of mutations in the genes encoding melatonin receptors was already demonstrated in ASD [175] as well as the positive effects on sleep and behavior after the administration of the melatonin receptor agonist ramelteon [176].  Considering that the rise of the endogenous melatonin concen-tration i s  o f t e n  u s e d  a s  a  m a r k e r  o f  a  p a r t i c u l a r  p h a s e  o f  t he  c ir-cadian rhythm (i.e. nighttime), reduction in nocturnal melatonin peak leads to a dysregulation of the temporal machinery, which may be expressed by deficient sleep consolidation and difficulty in initiating or maintaining sleep. Melatonin also affects the synchro-nicity of clock gene expression (Per1, Per2, Bmal1, Rev-erbα, Clock, and Cry1) in both central and peripheral target tissues [177]. In addition, pinealectomy, in animal models, abolishes the rhythmic expression of Per1 in the pars tuberalis [178] and results in desyn-chronized Per1 and Per2 expressions in the SCN [179]. Agomelatine, a melatonin agonist, was effective and well-tolerated for treating insomnia and regulate circadian rhythms of sleep and temperature in ASD [180]. Taken together, these studies underlined the major role of neuroendocrine responses of melatonin in the regulation of rhythms including the sleep-wake, and",
            "page": 6
        },
        "id": "1422"
    },
    {
        "document": "MJH",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\nsincenoDAPIenters(Figure S26,SupportingInformation).In-\nstead,thecellsrespondtothelightaloneandhavetimetomain-\ntain control of their movement because they are not being de-\nstroyed. It is presumed the cells were moving away from the\nlightsinceweobservedaslightincreaseinthecells’area(Figure\nS26, Supporting Information). This is additional evidence that\nthe VDA in plasmon-driven MJH is producing mechanical ac-\ntionthatisdiﬀerentthantheactioninducedbylightalone.The\nMJHwithoutlightactivationhasnoeﬀectontheareaofthecell\nnor does DAPI enter the cell within the time window of the ex-\nperiment(Figure S27,SupportingInformation).These changes\nare not observed in the cells without any treatment; only Cell-\nMaskGreenwasaddedtovisualizethecellmembraneandDAPI\ntomeasuretheintegrityofthecellmembrane(Figure S28,S up-\nportingInformation).\n2.8.LethalConcentrationofPlasmon-DrivenMJHs\nA clonogenic assay was conducted to conﬁrm that cancer cells\ntreatedbyplasmon-drivenMJHarekilleduponNIR-lightactiva-\ntion (Figure6). Three molecules were tested: the most VDA ac-\ntiveBL-204,themediumVDAactiveBL-141-2,andthelowVDA\nactive Cy7-amine. The lethal concentration to kill the cell popu-\nlation by 50% (VDA IC50) was found to be 45, 65, and 175 nm,\nrespectively. The lethal concentrations to eradicate 100% of the\ncancer cells were 75, 100, and 500 nm, respectively. This result\nconﬁrmsthatBL-204isoneofthemostactivecompoundsinthis\nlibrarytoeradicatecancercells.Thiswasaccomplishedbyincu-\nbating the MJH molecules with the A375 cells for 50 min and\nthen activation of the plasmon-driven MJH using 730 nm NIR-\nlightat80mWcm−2for10min.\n2.9.PredictedOctanol–WaterPartitionCoeﬃcient(logPValue)in\nCyanine-BasedMJH\nTodetermineifthehighercellmembranepermeabilizationactiv-\nitywassimplyduetohighercellmembraneaﬃnityratherthan\nthe EPI, we calculated the octanol–water partition coeﬃcient,\nlogP value, of the MJH using a logP calculator. This parameter\nindicates the lipophilicity of the MJH to the lipid bilayers.[40,41]\nThe higher the value the more likely the MJH will bind to the\nlipid bilayers. The protonation state of the MJH strongly inﬂu-\nences the polarity of the molecules and hence the logP values.\nThe logP values were calculated considering the charged state\n(amine protonated or carboxylic acid ionized) of the side chain\n(FigureS31A, Supporting Information) or in the neutral state\n(FigureS31B,SupportingInformation)ifnoionizationwaspre-\nsumed. The charged state is more likely to occur at pH ≈7.4 in\nthemediumsincethepKaofthedeprotonationofalkylaminesis≈9.5–11andoftheionizationofthecarboxylicacidis ≈5.The\nlogP values do not fully correlate with the ability to permeabi-\nlize cell membranes (Figure S31C,D, Supporting Information).\nThis supports the ﬁnding that the aﬃnity of MJH to cell mem-\nbranesisnotthemainfactorresponsibleforVDA-mediatedcell\nmembranepermeabilization.TherearehighlyVDAactiveMJH\nsuchasBL-204,GL-308-2,andGL-356-2withrelativelylowlogP\nvalues.Incontrast,therearemoleculessuchasBL-141-1andBL-\n142 with relatively high logP values that should have high con-\ncentrationsinthelipidbilayersbutarenotthemostVDAactive.\nThis is evidence that the VDA activities are not simply",
            "page": 9
        },
        "id": "2115"
    },
    {
        "document": "MJH",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n2.11.TheEﬀectofContactTimeontheCytotoxicityofMJH\nUsingaCrystalVioletTest\nThecontacttimeduringtheincubationofMJHwithA375cells\nhasastrongeﬀectonthecytotoxicity.Generally,MJHatashort\ncontact time ( ≈40 min) showed little to no cytotoxicity (Figure\nS39,SupportingInformation).However, atlongcontact time(1\nor 2 days) MJH became toxic, likely through a slow cytotoxic\nmechanism.Interestingly,insomecases,wehaveobservedthat\nMJHsuchasGL-261-2canincreasethecellviabilityatshortcon-\ntacttimeasshowninFigure S39C(SupportingInformation)and\nGL-286atlowconcentrations( <1μm)asshowninF igure S39D\n(Supporting Information). For the short contact times of 40 or\n50min,theMJHwasincubatedwithA375cells,thentheexcess\nwasremovedbycentrifugation,andthecellswereculturedfor2\nd.Thecellviabilitywasthenmeasuredbyacrystalviolettest.For\nthe long contact time, the MJH were incubated with A375 cells\nfor1or2daysandthentheviabilitywasimmediatelymeasured\nbyacrystalviolettest(Figures S40,S41,SupportingInformation).\nThemildeﬀectsatshortcontacttime( ≈40–50min)arethrough\na slow cell killing mechanism, likely apoptosis since the more\ncomplete killing is observed after culturing the cells for 2 days.\nThiscontrastswiththenecroticcelldeathinducedbyNIR-light-\nactivated VDA that takes 10 min to kill the cells. These are two\ndistinctive,andinsomeaspectsopposing,mechanismsofaction\nforcelldeath.[42,43]\nThequestionthatarisesregardingtheMJHcytotoxicitywith-\noutlightactivationis:DoestheMJHtoxicitydirectlycorrelateto\nthe VDA activity? To answer this question, we built 2D correla-\ntionplotscomparingtheVDAactivityunderlightactivationver-\nsusthetoxicityofthemoleculeswithoutlightactivation(Figure\nS42,SupportingInformation).Thereisnodirectcorrelationbe-\ntween the VDA activity and inherent toxicity. More importantly,\nBL-142, with relatively low inherent toxicity with respect to oth-\ners,retainshighVDAactivity.TheVDAactivitywasmeasuredby\nﬂowcytometryat10minimmediatelyafterlighttreatmentwhile\ntheinherenttoxicitywasmeasuredbycrystalviolettestaftercon-\ntinuousMJHexposuretothecellsfor2days.\n2.12.TheEﬀectofContactTimeintheCytotoxicityofMJHUsing\nClonogenicAssay\nFor additional assessment of the VDA activity versus the inher-\nent toxicity, both properties were measured using a clonogenic\nassay for cell viability. The exposure time in both experiments\nwas equal (Figure S43, Supporting Information), 7 h for both,\nfollowed by culture of the cells for 7 days to allow colony for-\nmation.Thecellsurvivalwascalculatedattheendofthecolony\nformation(Figures S44,S47,SupportingInformation).Lowerin-\nherenttoxicitymoleculesfromFigure S42(SupportingInforma-\ntion) were included in the analysis; additional molecules were\nsynthesized seeking to reduce their inherent toxicity. For exam-\nple,fromFigure S42(SupportingInformation)weidentiﬁedthat\nthecarboxylatedGL-261-2waslesstoxicthantheaminocyanines.\nFollowingthisobservation,wesynthesizedBL-242(Figure S43E,\nSupportingInformation).Theacetylationoftheaminesuchasin\nGL-362-2 enhanced the toxicity (Figure S43E, Supporting Infor-\nmation).Overall,nodirectcorrelationbetweenthelight-activatedVDAactivity,andtheinherenttoxicitywasobserved(Figure S43A\nvs FigureS43B, Supporting Information). The ratio of inherent\ntoxicity/VDA activity was de",
            "page": 10
        },
        "id": "2180"
    },
    {
        "document": "M. Mesch",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "A.Atwater,A.Polman, Nat.Mater. 2010,9,205.\n[6] J.Langer,D.JimenezDeAberasturi,J.Aizpurua,R.A.Alvarez-Puebla,\nB. Auguié, J. J. Baumberg, G. C. Bazan, S. E. J. Bell, A. Boisen, A. G.\nBrolo, J. Choo, D. Cialla-May, V. Deckert, L. Fabris, K. Faulds, F. J.\nGarcíaDeAbajo,R.Goodacre,D.Graham,A.J.Haes,C.L.Haynes,\nC. Huck, T. Itoh, M. Käll, J. Kneipp, N. A. Kotov, H. Kuang, E. C. Le\nRu,H.K.Lee,J.-F.Li,X.Y.Ling,etal., ACSNano 2020,14,28.\n[7] B. Sharma, R. R. Frontiera, A.-I. Henry, E. Ringe, R. P. Van Duyne,\nMater.Today 2012,15,16.\n[8] N. Liu, M. Mesch, T. Weiss, M. Hentschel, H. Giessen, Nano Lett.\n2010,10,2342.\n[9] J. N. Anker, W. P. Hall, O. Lyandres, N. C. Shah, J. Zhao, R. P. Van\nDuyne,Nat.Mater. 2008,7,442.\n[10] K. C. Bantz, A. F. Meyer, N. J. Wittenberg, H. Im, Ö. Kurtulus, S. H.\nLee,N.C.Lindquist,S.-H.Oh,C.L.Haynes, Phys.Chem.Chem.Phys.\n2011,13,11551.\n[11] R.Bardhan,S.Lal,A.Joshi,N.J.Halas, Acc.Chem.Res. 2011,44,936.\n[12] O. Neumann, A. S. Urban, J. Day, S. Lal, P. Nordlander, N. J. Halas,\nACSNano 2013,7,42.\n[13] J.G.Smith,J.A.Faucheaux,P.K.Jain, NanoToday 2015,10,67.\n[14] L. Zhou, Y. Tan, J. Wang, W. Xu, Y. Yuan, W. Cai, S. Zhu, J. Zhu, Nat.\nPhotonics2016,10,393.\n[15] S.Linic,P.Christopher,D.B.Ingram, Nat.Mater. 2011,10,911.\n[16] Z. Zheng, W. Xie, B. Huang, Y. Dai, Chem., A Eur. J. 2018,24,\n18322.\n[17] P. R. West, S. Ishii, G. V. Naik, N. K. Emani, V. M. Shalaev, A.\nBoltasseva, LaserPhoton.Rev. 2010,4,795.\n[18] G.V.Naik,V.M.Shalaev,A.Boltasseva, Adv.Mater. 2013,25,3264.\n[19] W.A.Murray,W.L.Barnes, Adv.Mater. 2007,19,3771.\n[20] Y.Cui,A.Lauchner,A.Manjavacas,F.J.GarcíaDeAbajo,N.J.Halas,\nP.Nordlander, NanoLett. 2016,16,6390.\n[21] A.Lauchner,A.E.Schlather,A.Manjavacas,Y.Cui,M.J.Mcclain,G.\nJ. Stec, F. J. García De Abajo, P. Nordlander, N. J. Halas, Nano Lett.\n2015,15,6208.\n[22] T.-C.Hung,B.Kiraly,J.H.Strik,A.A.Khajetoorians,D.Wegner, Nano\nLett.20",
            "page": 11
        },
        "id": "2241"
    },
    {
        "document": "H. Im",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "A.Atwater,A.Polman, Nat.Mater. 2010,9,205.\n[6] J.Langer,D.JimenezDeAberasturi,J.Aizpurua,R.A.Alvarez-Puebla,\nB. Auguié, J. J. Baumberg, G. C. Bazan, S. E. J. Bell, A. Boisen, A. G.\nBrolo, J. Choo, D. Cialla-May, V. Deckert, L. Fabris, K. Faulds, F. J.\nGarcíaDeAbajo,R.Goodacre,D.Graham,A.J.Haes,C.L.Haynes,\nC. Huck, T. Itoh, M. Käll, J. Kneipp, N. A. Kotov, H. Kuang, E. C. Le\nRu,H.K.Lee,J.-F.Li,X.Y.Ling,etal., ACSNano 2020,14,28.\n[7] B. Sharma, R. R. Frontiera, A.-I. Henry, E. Ringe, R. P. Van Duyne,\nMater.Today 2012,15,16.\n[8] N. Liu, M. Mesch, T. Weiss, M. Hentschel, H. Giessen, Nano Lett.\n2010,10,2342.\n[9] J. N. Anker, W. P. Hall, O. Lyandres, N. C. Shah, J. Zhao, R. P. Van\nDuyne,Nat.Mater. 2008,7,442.\n[10] K. C. Bantz, A. F. Meyer, N. J. Wittenberg, H. Im, Ö. Kurtulus, S. H.\nLee,N.C.Lindquist,S.-H.Oh,C.L.Haynes, Phys.Chem.Chem.Phys.\n2011,13,11551.\n[11] R.Bardhan,S.Lal,A.Joshi,N.J.Halas, Acc.Chem.Res. 2011,44,936.\n[12] O. Neumann, A. S. Urban, J. Day, S. Lal, P. Nordlander, N. J. Halas,\nACSNano 2013,7,42.\n[13] J.G.Smith,J.A.Faucheaux,P.K.Jain, NanoToday 2015,10,67.\n[14] L. Zhou, Y. Tan, J. Wang, W. Xu, Y. Yuan, W. Cai, S. Zhu, J. Zhu, Nat.\nPhotonics2016,10,393.\n[15] S.Linic,P.Christopher,D.B.Ingram, Nat.Mater. 2011,10,911.\n[16] Z. Zheng, W. Xie, B. Huang, Y. Dai, Chem., A Eur. J. 2018,24,\n18322.\n[17] P. R. West, S. Ishii, G. V. Naik, N. K. Emani, V. M. Shalaev, A.\nBoltasseva, LaserPhoton.Rev. 2010,4,795.\n[18] G.V.Naik,V.M.Shalaev,A.Boltasseva, Adv.Mater. 2013,25,3264.\n[19] W.A.Murray,W.L.Barnes, Adv.Mater. 2007,19,3771.\n[20] Y.Cui,A.Lauchner,A.Manjavacas,F.J.GarcíaDeAbajo,N.J.Halas,\nP.Nordlander, NanoLett. 2016,16,6390.\n[21] A.Lauchner,A.E.Schlather,A.Manjavacas,Y.Cui,M.J.Mcclain,G.\nJ. Stec, F. J. García De Abajo, P. Nordlander, N. J. Halas, Nano Lett.\n2015,15,6208.\n[22] T.-C.Hung,B.Kiraly,J.H.Strik,A.A.Khajetoorians,D.Wegner, Nano\nLett.20",
            "page": 11
        },
        "id": "2255"
    },
    {
        "document": "M.G.Hanna",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "2360"
    },
    {
        "document": "G.Majno",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "2370"
    },
    {
        "document": "M.Misiura",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "2393"
    },
    {
        "document": "J.M.Tour",
        "metadata": {
            "originalPdf": "10c5984f-d755-4b18-be0b-84d66e2cdd8a.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "2400"
    },
    {
        "document": "Miu P",
        "metadata": {
            "originalPdf": "0dfc0ca6-41c5-4a69-a201-6826b91ff714.pdf",
            "originalText": ", Zarrinpar A, Miu P, Panda S (2014) Time-restricted feeding is a preventative and\ntherapeutic intervention against diverse nutritional challenges. Cell Metab 20:991–1005\n87. Hatori M, Vollmers C, Zarrinpar A, Ditacchio L, Bushong EA, Gill S, Leblanc M, Chaix A,\nJoens M, Fitzpatrick JA, Ellisman MH, Panda S (2012) Time-restricted feeding withoutreducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab15:848–860.\n88. Liu Z, Huang M, Wu X, Shi G, Xing L, Dong Z, Qu Z, Yan J, Yang L, Panda S, Xu Y (2014)\nPER1 phosphorylation speciﬁes feeding rhythm in mice. Cell Rep 7:1509–1520\n89. Garaulet M, Gomez-Abellan P, Alburquerque-Bejar JJ, Lee YC, Ordovas JM, Scheer FA\n(2013) Timing of food intake predicts weight loss effectiveness. Int J Obes (Lond) 37:604–611\n90. Gill S, Panda S (2015) A smartphone app reveals erratic diurnal eating patterns in humans that\ncan be modulated for health beneﬁts. Cell Metab 22:789–798\n91. Marinac CR, Natarajan L, Sears DD, Gallo LC, Hartman SJ, Arredondo E, Patterson RE\n(2015) Prolonged nightly fasting and breast cancer risk: ﬁndings from NHANES (2009–2010).\nCancer Epidemiol Biomarkers Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc PrevOncol 24:783–789458 B. Sarkisian et al.",
            "page": 15
        },
        "id": "2587"
    },
    {
        "document": "Miu P",
        "metadata": {
            "originalPdf": "Circadian Regulation of Metabolism in Health and Diseases.pdf",
            "originalText": ", Zarrinpar A, Miu P, Panda S (2014) Time-restricted feeding is a preventative and\ntherapeutic intervention against diverse nutritional challenges. Cell Metab 20:991–1005\n87. Hatori M, Vollmers C, Zarrinpar A, Ditacchio L, Bushong EA, Gill S, Leblanc M, Chaix A,\nJoens M, Fitzpatrick JA, Ellisman MH, Panda S (2012) Time-restricted feeding withoutreducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab15:848–860.\n88. Liu Z, Huang M, Wu X, Shi G, Xing L, Dong Z, Qu Z, Yan J, Yang L, Panda S, Xu Y (2014)\nPER1 phosphorylation speciﬁes feeding rhythm in mice. Cell Rep 7:1509–1520\n89. Garaulet M, Gomez-Abellan P, Alburquerque-Bejar JJ, Lee YC, Ordovas JM, Scheer FA\n(2013) Timing of food intake predicts weight loss effectiveness. Int J Obes (Lond) 37:604–611\n90. Gill S, Panda S (2015) A smartphone app reveals erratic diurnal eating patterns in humans that\ncan be modulated for health beneﬁts. Cell Metab 22:789–798\n91. Marinac CR, Natarajan L, Sears DD, Gallo LC, Hartman SJ, Arredondo E, Patterson RE\n(2015) Prolonged nightly fasting and breast cancer risk: ﬁndings from NHANES (2009–2010).\nCancer Epidemiol Biomarkers Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc PrevOncol 24:783–789458 B. Sarkisian et al.",
            "page": 15
        },
        "id": "2876"
    },
    {
        "document": "Tordjman S",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3509"
    },
    {
        "document": "DeMand A",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3535"
    },
    {
        "document": "Malow BA",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3536"
    },
    {
        "document": "Meir D",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3551"
    },
    {
        "document": "Hadjez J",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3554"
    },
    {
        "document": "Garstang J",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3556"
    },
    {
        "document": "Wallis M",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3557"
    },
    {
        "document": "Aman MG",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3559"
    },
    {
        "document": "Kulman G",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3561"
    },
    {
        "document": "Maas APHM",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3569"
    },
    {
        "document": "Smits MG",
        "metadata": {
            "originalPdf": "4a98b445-1f09-4a39-8425-dd23b7140e64.pdf",
            "originalText": "/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 2011; 25(4): 767-76.  [http://dx.doi.org/10.1016/j.bbi.2011.02.002] [PMID: 21333736] [150] Malow BA, McGrew SG. Sleep and quality of life in autism.Sleep and quality of life in medical illness 2008; 221-7.  [http://dx.doi.org/10.1007/978-1-60327-343-5_24] [151] Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive be-haviors. Sleep Med 2018; 44: 61-6.  [http://dx.doi.org/10.1016/j.sleep.2018.01.008] [PMID: 29530371] [152] Turygin N, Matson JL, Tureck K. ADHD symptom prevalence and risk factors in a sample of toddlers with ASD or who are at risk for developmental delay. Res Dev Disabil 2013; 34(11): 4203-9.  [http://dx.doi.org/10.1016/j.ridd.2013.07.020] [PMID: 24077069] [153] da Silveira Cruz-Machado S, Guissoni Campos LM, Fadini CC, Anderson G, Markus RP, Pinato L. Disrupted nocturnal melatonin rhythm in Autism: correlation with TNF and sleep disturbances submitted [154] Muscatello RA, Corbett BA. Comparing the effects of age, pubertal development, and symptom profile on cortisol rhythm in children and adolescents with autism spectrum disorder. Autism Res 2018; 11(1): 110-20.  [http://dx.doi.org/10.1002/aur.1879] [PMID: 29030905] [155] Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14(10): 20508-42.  [http://dx.doi.org/10.3390/ijms141020508] [PMID: 24129182] [156] Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief re-port: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25(6): 641-54.  [http://dx.doi.org/10.1007/BF02178193] [PMID: 8720032] [157] Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-9.  [http://dx.doi.org/10.1111/j.1365-2214.2006.00616.x] [PMID: 16919138] [158] Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27(3): 254-89.  [http://dx.doi.org/10.1016/j.ridd.2005.03.003] [PMID: 16002261] [159] Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21(1): 31-4.  [PMID: 11455326] [160] Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low ma-ternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil 2018; 82: 79-89.  [http://dx.doi.org/10.1016/j.ridd.2018.02.017] [PMID: 29501372] [161] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.  [http://dx.doi.org/10.1111/j.1469-8749.2011.03980.x] [PMID: 21518346] [162] Johansson AEE, Dorman",
            "page": 13
        },
        "id": "3570"
    },
    {
        "document": "MJH",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\nsincenoDAPIenters(Figure S26,SupportingInformation).In-\nstead,thecellsrespondtothelightaloneandhavetimetomain-\ntain control of their movement because they are not being de-\nstroyed. It is presumed the cells were moving away from the\nlightsinceweobservedaslightincreaseinthecells’area(Figure\nS26, Supporting Information). This is additional evidence that\nthe VDA in plasmon-driven MJH is producing mechanical ac-\ntionthatisdiﬀerentthantheactioninducedbylightalone.The\nMJHwithoutlightactivationhasnoeﬀectontheareaofthecell\nnor does DAPI enter the cell within the time window of the ex-\nperiment(Figure S27,SupportingInformation).These changes\nare not observed in the cells without any treatment; only Cell-\nMaskGreenwasaddedtovisualizethecellmembraneandDAPI\ntomeasuretheintegrityofthecellmembrane(Figure S28,S up-\nportingInformation).\n2.8.LethalConcentrationofPlasmon-DrivenMJHs\nA clonogenic assay was conducted to conﬁrm that cancer cells\ntreatedbyplasmon-drivenMJHarekilleduponNIR-lightactiva-\ntion (Figure6). Three molecules were tested: the most VDA ac-\ntiveBL-204,themediumVDAactiveBL-141-2,andthelowVDA\nactive Cy7-amine. The lethal concentration to kill the cell popu-\nlation by 50% (VDA IC50) was found to be 45, 65, and 175 nm,\nrespectively. The lethal concentrations to eradicate 100% of the\ncancer cells were 75, 100, and 500 nm, respectively. This result\nconﬁrmsthatBL-204isoneofthemostactivecompoundsinthis\nlibrarytoeradicatecancercells.Thiswasaccomplishedbyincu-\nbating the MJH molecules with the A375 cells for 50 min and\nthen activation of the plasmon-driven MJH using 730 nm NIR-\nlightat80mWcm−2for10min.\n2.9.PredictedOctanol–WaterPartitionCoeﬃcient(logPValue)in\nCyanine-BasedMJH\nTodetermineifthehighercellmembranepermeabilizationactiv-\nitywassimplyduetohighercellmembraneaﬃnityratherthan\nthe EPI, we calculated the octanol–water partition coeﬃcient,\nlogP value, of the MJH using a logP calculator. This parameter\nindicates the lipophilicity of the MJH to the lipid bilayers.[40,41]\nThe higher the value the more likely the MJH will bind to the\nlipid bilayers. The protonation state of the MJH strongly inﬂu-\nences the polarity of the molecules and hence the logP values.\nThe logP values were calculated considering the charged state\n(amine protonated or carboxylic acid ionized) of the side chain\n(FigureS31A, Supporting Information) or in the neutral state\n(FigureS31B,SupportingInformation)ifnoionizationwaspre-\nsumed. The charged state is more likely to occur at pH ≈7.4 in\nthemediumsincethepKaofthedeprotonationofalkylaminesis≈9.5–11andoftheionizationofthecarboxylicacidis ≈5.The\nlogP values do not fully correlate with the ability to permeabi-\nlize cell membranes (Figure S31C,D, Supporting Information).\nThis supports the ﬁnding that the aﬃnity of MJH to cell mem-\nbranesisnotthemainfactorresponsibleforVDA-mediatedcell\nmembranepermeabilization.TherearehighlyVDAactiveMJH\nsuchasBL-204,GL-308-2,andGL-356-2withrelativelylowlogP\nvalues.Incontrast,therearemoleculessuchasBL-141-1andBL-\n142 with relatively high logP values that should have high con-\ncentrationsinthelipidbilayersbutarenotthemostVDAactive.\nThis is evidence that the VDA activities are not simply",
            "page": 9
        },
        "id": "3930"
    },
    {
        "document": "MJH",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n2.11.TheEﬀectofContactTimeontheCytotoxicityofMJH\nUsingaCrystalVioletTest\nThecontacttimeduringtheincubationofMJHwithA375cells\nhasastrongeﬀectonthecytotoxicity.Generally,MJHatashort\ncontact time ( ≈40 min) showed little to no cytotoxicity (Figure\nS39,SupportingInformation).However, atlongcontact time(1\nor 2 days) MJH became toxic, likely through a slow cytotoxic\nmechanism.Interestingly,insomecases,wehaveobservedthat\nMJHsuchasGL-261-2canincreasethecellviabilityatshortcon-\ntacttimeasshowninFigure S39C(SupportingInformation)and\nGL-286atlowconcentrations( <1μm)asshowninF igure S39D\n(Supporting Information). For the short contact times of 40 or\n50min,theMJHwasincubatedwithA375cells,thentheexcess\nwasremovedbycentrifugation,andthecellswereculturedfor2\nd.Thecellviabilitywasthenmeasuredbyacrystalviolettest.For\nthe long contact time, the MJH were incubated with A375 cells\nfor1or2daysandthentheviabilitywasimmediatelymeasured\nbyacrystalviolettest(Figures S40,S41,SupportingInformation).\nThemildeﬀectsatshortcontacttime( ≈40–50min)arethrough\na slow cell killing mechanism, likely apoptosis since the more\ncomplete killing is observed after culturing the cells for 2 days.\nThiscontrastswiththenecroticcelldeathinducedbyNIR-light-\nactivated VDA that takes 10 min to kill the cells. These are two\ndistinctive,andinsomeaspectsopposing,mechanismsofaction\nforcelldeath.[42,43]\nThequestionthatarisesregardingtheMJHcytotoxicitywith-\noutlightactivationis:DoestheMJHtoxicitydirectlycorrelateto\nthe VDA activity? To answer this question, we built 2D correla-\ntionplotscomparingtheVDAactivityunderlightactivationver-\nsusthetoxicityofthemoleculeswithoutlightactivation(Figure\nS42,SupportingInformation).Thereisnodirectcorrelationbe-\ntween the VDA activity and inherent toxicity. More importantly,\nBL-142, with relatively low inherent toxicity with respect to oth-\ners,retainshighVDAactivity.TheVDAactivitywasmeasuredby\nﬂowcytometryat10minimmediatelyafterlighttreatmentwhile\ntheinherenttoxicitywasmeasuredbycrystalviolettestaftercon-\ntinuousMJHexposuretothecellsfor2days.\n2.12.TheEﬀectofContactTimeintheCytotoxicityofMJHUsing\nClonogenicAssay\nFor additional assessment of the VDA activity versus the inher-\nent toxicity, both properties were measured using a clonogenic\nassay for cell viability. The exposure time in both experiments\nwas equal (Figure S43, Supporting Information), 7 h for both,\nfollowed by culture of the cells for 7 days to allow colony for-\nmation.Thecellsurvivalwascalculatedattheendofthecolony\nformation(Figures S44,S47,SupportingInformation).Lowerin-\nherenttoxicitymoleculesfromFigure S42(SupportingInforma-\ntion) were included in the analysis; additional molecules were\nsynthesized seeking to reduce their inherent toxicity. For exam-\nple,fromFigure S42(SupportingInformation)weidentiﬁedthat\nthecarboxylatedGL-261-2waslesstoxicthantheaminocyanines.\nFollowingthisobservation,wesynthesizedBL-242(Figure S43E,\nSupportingInformation).Theacetylationoftheaminesuchasin\nGL-362-2 enhanced the toxicity (Figure S43E, Supporting Infor-\nmation).Overall,nodirectcorrelationbetweenthelight-activatedVDAactivity,andtheinherenttoxicitywasobserved(Figure S43A\nvs FigureS43B, Supporting Information). The ratio of inherent\ntoxicity/VDA activity was de",
            "page": 10
        },
        "id": "3987"
    },
    {
        "document": "M. Mesch",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "A.Atwater,A.Polman, Nat.Mater. 2010,9,205.\n[6] J.Langer,D.JimenezDeAberasturi,J.Aizpurua,R.A.Alvarez-Puebla,\nB. Auguié, J. J. Baumberg, G. C. Bazan, S. E. J. Bell, A. Boisen, A. G.\nBrolo, J. Choo, D. Cialla-May, V. Deckert, L. Fabris, K. Faulds, F. J.\nGarcíaDeAbajo,R.Goodacre,D.Graham,A.J.Haes,C.L.Haynes,\nC. Huck, T. Itoh, M. Käll, J. Kneipp, N. A. Kotov, H. Kuang, E. C. Le\nRu,H.K.Lee,J.-F.Li,X.Y.Ling,etal., ACSNano 2020,14,28.\n[7] B. Sharma, R. R. Frontiera, A.-I. Henry, E. Ringe, R. P. Van Duyne,\nMater.Today 2012,15,16.\n[8] N. Liu, M. Mesch, T. Weiss, M. Hentschel, H. Giessen, Nano Lett.\n2010,10,2342.\n[9] J. N. Anker, W. P. Hall, O. Lyandres, N. C. Shah, J. Zhao, R. P. Van\nDuyne,Nat.Mater. 2008,7,442.\n[10] K. C. Bantz, A. F. Meyer, N. J. Wittenberg, H. Im, Ö. Kurtulus, S. H.\nLee,N.C.Lindquist,S.-H.Oh,C.L.Haynes, Phys.Chem.Chem.Phys.\n2011,13,11551.\n[11] R.Bardhan,S.Lal,A.Joshi,N.J.Halas, Acc.Chem.Res. 2011,44,936.\n[12] O. Neumann, A. S. Urban, J. Day, S. Lal, P. Nordlander, N. J. Halas,\nACSNano 2013,7,42.\n[13] J.G.Smith,J.A.Faucheaux,P.K.Jain, NanoToday 2015,10,67.\n[14] L. Zhou, Y. Tan, J. Wang, W. Xu, Y. Yuan, W. Cai, S. Zhu, J. Zhu, Nat.\nPhotonics2016,10,393.\n[15] S.Linic,P.Christopher,D.B.Ingram, Nat.Mater. 2011,10,911.\n[16] Z. Zheng, W. Xie, B. Huang, Y. Dai, Chem., A Eur. J. 2018,24,\n18322.\n[17] P. R. West, S. Ishii, G. V. Naik, N. K. Emani, V. M. Shalaev, A.\nBoltasseva, LaserPhoton.Rev. 2010,4,795.\n[18] G.V.Naik,V.M.Shalaev,A.Boltasseva, Adv.Mater. 2013,25,3264.\n[19] W.A.Murray,W.L.Barnes, Adv.Mater. 2007,19,3771.\n[20] Y.Cui,A.Lauchner,A.Manjavacas,F.J.GarcíaDeAbajo,N.J.Halas,\nP.Nordlander, NanoLett. 2016,16,6390.\n[21] A.Lauchner,A.E.Schlather,A.Manjavacas,Y.Cui,M.J.Mcclain,G.\nJ. Stec, F. J. García De Abajo, P. Nordlander, N. J. Halas, Nano Lett.\n2015,15,6208.\n[22] T.-C.Hung,B.Kiraly,J.H.Strik,A.A.Khajetoorians,D.Wegner, Nano\nLett.20",
            "page": 11
        },
        "id": "4048"
    },
    {
        "document": "H. Im",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "A.Atwater,A.Polman, Nat.Mater. 2010,9,205.\n[6] J.Langer,D.JimenezDeAberasturi,J.Aizpurua,R.A.Alvarez-Puebla,\nB. Auguié, J. J. Baumberg, G. C. Bazan, S. E. J. Bell, A. Boisen, A. G.\nBrolo, J. Choo, D. Cialla-May, V. Deckert, L. Fabris, K. Faulds, F. J.\nGarcíaDeAbajo,R.Goodacre,D.Graham,A.J.Haes,C.L.Haynes,\nC. Huck, T. Itoh, M. Käll, J. Kneipp, N. A. Kotov, H. Kuang, E. C. Le\nRu,H.K.Lee,J.-F.Li,X.Y.Ling,etal., ACSNano 2020,14,28.\n[7] B. Sharma, R. R. Frontiera, A.-I. Henry, E. Ringe, R. P. Van Duyne,\nMater.Today 2012,15,16.\n[8] N. Liu, M. Mesch, T. Weiss, M. Hentschel, H. Giessen, Nano Lett.\n2010,10,2342.\n[9] J. N. Anker, W. P. Hall, O. Lyandres, N. C. Shah, J. Zhao, R. P. Van\nDuyne,Nat.Mater. 2008,7,442.\n[10] K. C. Bantz, A. F. Meyer, N. J. Wittenberg, H. Im, Ö. Kurtulus, S. H.\nLee,N.C.Lindquist,S.-H.Oh,C.L.Haynes, Phys.Chem.Chem.Phys.\n2011,13,11551.\n[11] R.Bardhan,S.Lal,A.Joshi,N.J.Halas, Acc.Chem.Res. 2011,44,936.\n[12] O. Neumann, A. S. Urban, J. Day, S. Lal, P. Nordlander, N. J. Halas,\nACSNano 2013,7,42.\n[13] J.G.Smith,J.A.Faucheaux,P.K.Jain, NanoToday 2015,10,67.\n[14] L. Zhou, Y. Tan, J. Wang, W. Xu, Y. Yuan, W. Cai, S. Zhu, J. Zhu, Nat.\nPhotonics2016,10,393.\n[15] S.Linic,P.Christopher,D.B.Ingram, Nat.Mater. 2011,10,911.\n[16] Z. Zheng, W. Xie, B. Huang, Y. Dai, Chem., A Eur. J. 2018,24,\n18322.\n[17] P. R. West, S. Ishii, G. V. Naik, N. K. Emani, V. M. Shalaev, A.\nBoltasseva, LaserPhoton.Rev. 2010,4,795.\n[18] G.V.Naik,V.M.Shalaev,A.Boltasseva, Adv.Mater. 2013,25,3264.\n[19] W.A.Murray,W.L.Barnes, Adv.Mater. 2007,19,3771.\n[20] Y.Cui,A.Lauchner,A.Manjavacas,F.J.GarcíaDeAbajo,N.J.Halas,\nP.Nordlander, NanoLett. 2016,16,6390.\n[21] A.Lauchner,A.E.Schlather,A.Manjavacas,Y.Cui,M.J.Mcclain,G.\nJ. Stec, F. J. García De Abajo, P. Nordlander, N. J. Halas, Nano Lett.\n2015,15,6208.\n[22] T.-C.Hung,B.Kiraly,J.H.Strik,A.A.Khajetoorians,D.Wegner, Nano\nLett.20",
            "page": 11
        },
        "id": "4062"
    },
    {
        "document": "M.G.Hanna",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "4178"
    },
    {
        "document": "G.Majno",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "4188"
    },
    {
        "document": "M.Misiura",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "4224"
    },
    {
        "document": "J.M.Tour",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "4231"
    },
    {
        "document": "M.Misiura",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "4237"
    },
    {
        "document": "J.M.Tour",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "4244"
    },
    {
        "document": "J.M.Tour",
        "metadata": {
            "originalPdf": "Advanced Materials - 2024.pdf",
            "originalText": "www.advancedsciencenews.com www.advmat.de\n[34] L.Shao,C.Fang,H.Chen,Y. C.Man,J.Wang,H.-Q.Lin, Nano Lett.\n2012,12,1424.\n[35] A. Mishra, R. K. Behera, P. K. Behera, B. K. Mishra, G. B. Behera,\nChem.Rev. 2000,100,1973.\n[36] C.Shi,J.B.Wu,D.Pan, J.Biomed.Opt. 2016,21,050901.\n[37] M. Falabella, H. J. Vernon, M. G. Hanna, S. M. Claypool, R. D. S.\nPitceathly, TrendsEndocrinol.Metab. 2021,32,224.\n[38] H.H.Szeto, Br.J.Pharmacol. 2014,171,2029.\n[39] A. J. Chicco, G. C. Sparagna, Am. J. Physiol., Cell Physiol. 2007,292,\nC33.\n[40] J.Sangster, J.Phys.Chem.Ref.Data 2009,18,1111.\n[41] E.A.Tehrany,F.Fournier,S.Desobry, J.FoodEng. 2004,64,315.\n[42] G.Majno,I.Joris, Am.J.Pathol. 1995,146,3.\n[43] S.L.Fink,B.T.Cookson, Infect.Immun. 2005,73,1907.[44] R. Zhang, L. Bursi, J. D. Cox, Y. Cui, C. M. Krauter, A. Alabastri, A.\nManjavacas,A.Calzolari,S.Corni,E.Molinari,E.A.Carter,F.J.García\nDeAbajo,H.Zhang,P.Nordlander, ACSNano 2017,11,7321.\n[45] L. Bursi, A. Calzolari, S. Corni, E. Molinari, ACS Photonics 2016,3,\n520.\n[46] A.L.Santos,D.Liu,A.K.Reed,A.M.Wyderka,A.VanVenrooy,J.T.Li,\nV. D. Li, M. Misiura, O. Samoylova, J. L. Beckham, C. Ayala-Orozco,\nA.B.Kolomeisky,L.B.Alemany,A.Oliver,G.P.Tegos,J.M.Tour, Sci.\nAdv.2022,8,eabm2055.\n[47] A. L. Santos, J. L. Beckham, D. Liu, G. Li, A. Van Venrooy, A. Oliver,\nG.P.Tegos,J.M.Tour, Adv.Sci.2023,10,2205781.\n[48] J. L. Beckham, A. R. Van Venrooy, S. Kim, G. Li, B. Li, G. Duret,\nD. Arnold, X. Zhao, J. T. Li, A. L. Santos, G. Chaudhry, D. Liu, J. T.\nRobinson,J.M.Tour, Nat.Nanotechnol. 2023,18,1051.\nAdv. Mater. 2024,2309910 ©2024Wiley-VCHGmbH 2309910(13of13)\n 15214095, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/adma.202309910 by Jinhee Kim - South Korea National Provision , Wiley Online Library on [08/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n",
            "page": 12
        },
        "id": "4256"
    },
    {
        "document": "MJH",
        "metadata": {
            "originalPdf": "58f827ca-8130-479f-bb97-926ce5777d22.pdf",
            "originalText": "EM media was removed and the cells were washed twice with \nPBS buffer. Then, a mixture of fresh DMEM media without phenol red \nand with the MJH was added to the cells. The DMEM without phenol \nred was from Gen Clone (25–501C) and was supplemented with 10% \nFBS (Corning, 35010CV), 1× MEM non-essential amino acid solution \n(Gibco, 11140050) and penicillin–streptomycin. The cells were incu -\nbated in the presence of the MJH at 37 °C and 5% CO2 for 30 min. Then \nthe cells were imaged and photoactivated in the confocal microscope \n(Nikon A1-Rsi, Plan Apo IR ×60/1.27 water immersion objective and \nNIS-Elements AR5.21.03 software for imaging and data analysis, Rice University Shared Equipment Authority).\nTemperature measurements\nThe cell permeabilization and flow cytometry analysis were conducted \nas described above. The temperature of the cell suspension was meas -\nured using a temperature probe (model SC-TT-K-30-36-PP, Omega \nEngineering) immersed in the media. The same process was repeated with the cell suspension on top of an ice bath. The temperature of the \ncell suspension was recorded in the same way during NIR light illu -\nmination. The temperature of the media remained constant at room \ntemperature (~20 °C) upon illumination of the media with 730 nm LED \nlight at 80 mW cm−2 for 10 min; a minor temperature increase of only \n0.4 °C was observed, which was attributed to the absorption of the \nillumination light by the media. Similarly, on ice, the temperature of \nthe media increased only 0.6 °C due to illumination by the 730 nm LED.\nROS scavenger experiments\nThe cell permeabilization and flow cytometry analysis were conducted \nas described above, but in this case, ROS scavengers (N -acetyl cysteine, \nthiourea, sodium azide, vitamin C or methionine) were added to the \ncell suspension and incubated for 1.5–2 h at 37 °C and 5% CO2 before \nany treatment to allow the antioxidants to interact first and protect \nthe cells.\nCrystal violet cell viability assay\nThe crystal violet assay was used to measure cell viability. This assay \nis based on the principle that viable cells adhere to the surface of the \ncell culture dish, keep growing and remain attached during cell culture \nunder standard conditions for a period of 1–2 days as well as during \nstaining under the conditions of the assay. In contrast, dead cells do \nnot adhere to the surface of the cell culture dish, do not grow and \ndetach easily during the manipulation steps of the assay, which include \nremoval of media, exchange with fresh media and washing with PBS \nbuffer. In the cell viability assay, A375 cells were collected, counted, and \nthen 20,000 A375 cells were added to each well of a 24-well culture plate \n(Corning) and cultured for 1 day under the standard incubation condi -\ntions of 37 °C and 5% CO2. The cells were treated in four experimental ",
            "page": 10
        },
        "id": "4611"
    }
]